Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Rudick

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Neurology|November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significanceRichard A Rudick
Cleveland Clinic Journal of Medicine|November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decideRichard A Rudick
The Lancet. Neurology|April 13, 2012
MS clinical trials: what can subgroup analyses teach us?Richard A Rudick
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's diseaseRichard A Rudick
Annals of Neurology|March 10, 2011
Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to goRichard A Rudick
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosisRichard A Rudick
Neurology|May 11, 2012
The elusive biomarker for personalized medicine in multiple sclerosis: the search continuesRichard A Rudick
Nature Reviews. Neurology|September 3, 2010
Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?Richard A Rudick
The Lancet. Neurology|June 8, 2013
MRI lesions: a surrogate for relapses in multiple sclerosis?Richard A Rudick, Gary Cutter
Current Opinion in Neurology|April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugsMegan Hyland, Richard A Rudick
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Neurology|November 12, 2003
Biologic impact of interferon antibodies, and complexities in assessing their clinical significanceRichard A Rudick
Cleveland Clinic Journal of Medicine|November 30, 2011
Multiple sclerosis, natalizumab, and PML: helping patients decideRichard A Rudick
The Lancet. Neurology|April 13, 2012
MS clinical trials: what can subgroup analyses teach us?Richard A Rudick
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2009
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's diseaseRichard A Rudick
Annals of Neurology|March 10, 2011
Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to goRichard A Rudick
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|July 2, 2004
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosisRichard A Rudick
Neurology|May 11, 2012
The elusive biomarker for personalized medicine in multiple sclerosis: the search continuesRichard A Rudick
Nature Reviews. Neurology|September 3, 2010
Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?Richard A Rudick
The Lancet. Neurology|June 8, 2013
MRI lesions: a surrogate for relapses in multiple sclerosis?Richard A Rudick, Gary Cutter
Current Opinion in Neurology|April 2, 2011
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugsMegan Hyland, Richard A Rudick
Pageof 11